Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT02487550
PHASE2

DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating

Sponsor: The First People's Hospital of Changzhou

View on ClinicalTrials.gov

Summary

The purpose of this study is to show if vaccination with autologous dendritic cells pulsed with tumor lysate in combination with Cytokine-Induced Killer Cell (CIK) can induce a measurable immune response in patients with renal cell carcinoma, and to evaluate the clinical effect of the regimen.

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

1200

Start Date

2015-08

Completion Date

2030-07

Last Updated

2015-07-01

Healthy Volunteers

No

Conditions

Interventions

BIOLOGICAL

DC-CIK

Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.

BIOLOGICAL

IL-2/IFN-α

Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.